ImpediMed Limited (ASX:IPD) Insider Acquires A$15,930.00 in Stock

ImpediMed Limited (ASX:IPD) insider Christine Emmanuel-Donnelly acquired 295,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average cost of A$0.05 ($0.04) per share, with a total value of A$15,930.00 ($10,344.16).

ImpediMed Stock Performance

The company has a debt-to-equity ratio of 2.80, a current ratio of 6.33 and a quick ratio of 6.23.

ImpediMed Company Profile

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.